AprilBio

IPO

SAFA enhances efficacy, safety and half-life

Chuncheon, South Korea · Founded 2013 · $251.1M raised

Headquarters
Chuncheon
Employees
51–200
Founded
2013
Business Model
B2B
Total Funding
$251.1M
Last Round
$251.1M Corporate RoundJun 2026
Rounds
1

About

AprilBio Co., Ltd. is a South Korean biopharmaceutical company founded in 2013 and headquartered in Chuncheon, Gangwon Province, specializing in the development of innovative therapeutics using its proprietary SAFA™ (anti-Serum Albumin Fab Associated) platform technology. The SAFA platform fuses human antibody fragments with an albumin binder to enhance drug efficacy, extend half-life, and minimize immunogenicity, enabling the development of next-generation treatments for autoimmune diseases and oncology. AprilBio's lead asset APB-A1, licensed to Lundbeck in a deal valued at up to $448M, has progressed through Phase 1b clinical trials, and the company secured approximately $247M (₩3,467 billion) in strategic investment from TKG Group and IMM Investment in 2026 to accelerate its expanding REMAP platform pipeline.

Summary

AprilBio is a Biotech company based in Chuncheon, South Korea, founded in 2013. It has raised $251.1M in total across 1 round, most recently a $251.1M Corporate Round round in Jun 2026.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Corporate RoundThird-Party AllotmentJun 2026
$251.1M

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

AprilBio on Indexed.vc
<a href="https://indexed.vc/companies/aprilbio"><img src="https://indexed.vc/api/badge/company/aprilbio" alt="AprilBio on Indexed.vc" width="260" height="76" /></a>